Shanghai/Boston, July 28, 2025—VelaVigo, a global biotech company focused on novel drug discovery and development, today announced the successful closing of over $60 million in Pre-A+ funding. The round was led by Shunwei Capital, with participation from Northern Light Venture Capital (NLVC), Han Kang Capital, Everest VC, Songqing Capital, and Lingang Lanwan Capital, among others, alongside increased commitments from existing investors such as HighLight Capital (HLC), Shanghai Healthcare Capital (SHC), Delian Capital, Legend Star, and Zoo Capital.

This new round of funding will be used to advance its core programs into global clinical trials, and to accelerate the development of both first-in-class (FIC) and best-in-class (BIC) drug candidates. Driven by a dual-engine model leveraging in-house innovation and global partnerships, VelaVigo has successfully developed a globally competitive pipeline, with more than ten programs having reached the preclinical candidate (PCC) stage. Among them, the lead oncology program is on track to enter clinical trials in both China and U.S. in 2025.

Since its inception in 2021, VelaVigo has completed three major financing rounds, including a $50 million angel round in November 2021, followed by a $50 million Pre-A round in December 2024.

Dr. Jing Li, Founder and CEO of VelaVigo, stated: “We are deeply grateful for the continued trust and support from our investors. VelaVigo maintains a highly efficient R&D model that demonstrates clear advantages in the innovation, quality, and speed. As our pipeline continues to advance, we have also established a high-caliber clinical development team. This round of financing will accelerate the clinical development of our lead candidates and facilitate our global strategic expansion efforts. We look forward to bringing breakthrough therapies to patients worldwide as soon as possible.”

VelaVigo has successfully established a sustainable “BD+VC” model. In November 2024, the company entered into an out-licensing agreement with U.S.-based Avenzo valued at $800 million, with a $50 million upfront and near-term milestone payment. In April 2025, VelaVigo signed a second out-licensing deal with the U.S. company Ollin, valued at $440 million. These landmark partnerships highlight the technological strength and commercial value of VelaVigo’s innovative pipeline.